Terms & Conditions

EVENITY® (romosozumab) will be prescribed by you to your patient for an indication for which EVENITY® is registered for therapeutic use in Australia.

By virtue of enrolling a patient in the Program, you have deemed it appropriate, based upon your independent medical evaluation of the patient, and the requirements for Program eligibility, to treat the patient with EVENITY®.

You have read and are familiar with the EVENITY® Approved Product Information (PI), including precautions and the recommended dosage regimen and method of administration. The approved PI is available from Amgen Australia Ph: 1800 803 638 or at www.amgen.com.au/Evenity.PI.

The patient's treatment with EVENITY®, including understanding of and compliance with all requirements is wholly the responsibility of you.

You shall be wholly responsible for explaining the relevant information to the patient. Amgen make no warranties, express or implied, regarding EVENITY® or its use in the patient.

Amgen, in its sole discretion, has the right to cease providing free product under the EVENITY® Co-Pay Program at any time.

You are required to obtain all appropriate consents for the patient to participate in the Program. Such consents shall permit Amgen and/or their third party suppliers, including Atlantis Health to collect, use, disclose and store the patient health information to administer the Program and their regulatory requirements such as reporting adverse events, as permitted by law. All patient personal information shared with Amgen will be de-identified except where Amgen has notified the physician that personal information that identifies one or more patients is required in order to comply with legal obligations in the state or territory in which the patient is being treated.

As part of the informed consent process, you must provide the patient and/or their authorised caregivers or guardians with:

You have read and understood the privacy statement provided and you agree with it. You understand that information relating to an adverse event, other safety finding or product quality complaint with an Amgen product that is identified during this activity will be forwarded to Amgen's Pharmacovigilance department, and possibly to health authorities when required.

You consent for Amgen's Pharmacovigilance department to contact you for follow-up in case an adverse event, other safety finding or product quality complaint is identified as part of this activity. You acknowledge that you must check with your patient before providing the requested follow-up information.

You represent and warrant that you have not been debarred as a physician pursuant to any applicable laws or regulations. Furthermore, there are no proceedings against you that could lead to your debarment. You also agree to immediately inform Atlantis Health in writing if any such proceeding is threatened or commenced.

Atlantis Health and/or Amgen reserve the right to change the Program Terms and Conditions at any time.

Repatha® (evolocumab) will be prescribed by you to your patient for an indication for which Repatha® is registered for therapeutic use in Australia.

By virtue of enrolling a patient in the Program, you have deemed it appropriate, based upon your independent medical evaluation of the patient, and the requirements for Program eligibility, to treat the patient with Repatha®.

You have read and are familiar with the Repatha® Approved Product Information (PI), including precautions and the recommended dosage and mode of administration. The approved PI is available from Amgen Australia Ph: 1800 803 638 or at www.amgen.com.au/Repatha.PI.

The patient's treatment with Repatha®, including understanding of and compliance with all requirements is wholly the responsibility of you.

You shall be wholly responsible for explaining the relevant information to the patient. Amgen make no warranties, express or implied, regarding Repatha® or its use in the patient.

Amgen, in its sole discretion, has the right to cease providing free product under the Repatha® Co-Pay Program at any time.

You are required to obtain all appropriate consents for the patient to participate in the Program. Such consents shall permit Amgen and/or their third party suppliers, including Atlantis Health to collect, use, disclose and store the patient's personal information to administer the Program and meet their regulatory requirements such as reporting adverse events, as permitted by law. All patient personal information shared with Amgen will be de-identified except where Amgen has notified the physician that personal information that identifies one or more patients is required in order to comply with legal obligations in the state or territory in which the patient is being treated.

As part of the informed consent process, you must provide the patient and/or their authorised caregivers or guardians with:

You have read and understood the privacy statement provided and you agree with it. You understand that information relating to an adverse event, other safety finding or product quality complaint with an Amgen product that is identified during this activity will be forwarded to Amgen's Pharmacovigilance department, and possibly to health authorities when required.

You consent for Amgen's Pharmacovigilance department to contact you for follow-up in case an adverse event, other safety finding or product quality complaint is identified as part of this activity. You acknowledge that you must check with your patient before providing the requested follow-up information.

You represent and warrant that you have not been debarred as a physician pursuant to any applicable laws or regulations. Furthermore, there are no proceedings against you that could lead to your debarment. You also agree to immediately inform Atlantis Health in writing if any such proceeding is threatened or commenced.

Atlantis Health and/or Amgen reserve the right to change the Program Terms and Conditions at any time.

As the nominated pharmacy/pharmacist (You), you agree to request EVENITY® for this patient through a pharmaceutical wholesaler. In order to claim back the cost of EVENITY® through the EVENITY® Co-Pay Program, EVENITY® should be ordered through your wholesaler subject to their standard trading terms.

EVENITY® is only intended for and supplied to the patient enrolled in the Program, and the patient must have a valid prescription for the product.

You agree that the treatment duration is at the discretion of the prescribing physician, and you will not dispense EVENITY® to any patient without a valid prescription.

You agree to be reimbursed monthly for any at no cost EVENITY® that has been dispensed as part of this Program, and only for the product for which a dispensing record has been lodged by the end of the preceding month.

You acknowledge that you will be reimbursed and agree to the rebate amount for your services in participating in the Program (as agreed and in accordance with the Program requirements). You must accurately report on any provision of services and product under this Program on the forms provided.

By participating in this Program, you confirm that you accept full responsibility for, and shall take all steps to maintain, appropriate records and ensure appropriate supply, storage, handling, distribution and usage of EVENITY® for this Program in accordance with any applicable laws and regulations.

You confirm that you will release your dispensing records for audit purposes to Atlantis Healthcare should we request it, within 30 days of the date of request.

You agree to promptly notify Atlantis Health in the event of a regulatory audit or inspection that relates to the administration of the product for this Program to a patient under this Program.

You agree to take any action necessary, as reasonably requested by Atlantis Health, to properly correct or address any deficiencies noted in the dispensing record for the Program or as a result of any regulatory inspection or audit of your records related to this Program.

By participating in this Program, you warrant that you have obtained consent from your pharmacy staff, or any other persons relating to this request, to forward their personal information to Atlantis Health, and to service providers or affiliated companies that assist us, on their behalf and that their information will be treated the same as outlined in the Privacy Statement.

By supplying your contact details, you also consent for Atlantis Health and/or Amgen to contact you for follow-up information if a safety report is identified. You agree that Atlantis Health and/or Amgen can contact you via email or telephone to seek further information regarding adverse events.

By participating in this Program, you acknowledge that you have read and understood the Australian Product Information for EVENITY®, and you understand that you can seek information for this product from the Consumer Medicine Information and the Product Information.

You agree to report all adverse events, other safety findings and product quality complaints immediately to Amgen's Pharmacovigilance team, and to obtain patient consent before providing personal information when making a report.

You represent and warrant that you have not been debarred as a pharmacist pursuant to any applicable laws or regulations. Furthermore, there are no proceedings against you that could lead to your debarment. You also agree to immediately inform Atlantis Health in writing if any such proceeding is threatened or commenced.

Atlantis Health and/or Amgen reserve the right to change the Program Terms and Conditions at any time.

As the nominated pharmacy/pharmacist (You), you agree to request Repatha® for this patient through a pharmaceutical wholesaler. In order to claim back the cost of Repatha® through the Repatha® Co-Pay Program, Repatha® should be ordered through your wholesaler subject to their standard trading terms.

Repatha® is only intended for and supplied to the patient enrolled in the Program, and the patient must have a valid prescription for the product.

You agree that the treatment duration is at the discretion of the prescribing physician, and you will not dispense Repatha® to any patient without a valid prescription.

You agree to be reimbursed monthly for any at no cost Repatha® that has been dispensed as part of this Program, and only for the product for which a dispensing record has been lodged by the end of the preceding month.

You acknowledge that you will be reimbursed and agree to the rebate amount for your services in participating in the Program (as agreed and in accordance with the Program requirements). You must accurately report on any provision of services and product under this Program on the forms provided.

By participating in this Program, you confirm that you accept full responsibility for, and shall take all steps to maintain, appropriate records and ensure appropriate supply, storage, handling, distribution and usage of Repatha® for this Program in accordance with any applicable laws and regulations.

You confirm that you will release your dispensing records for audit purposes to Atlantis Healthcare should we request it, within 30 days of the date of request.

You agree to promptly notify Atlantis Health in the event of a regulatory audit or inspection that relates to the administration of the product for this Program to a patient under this Program.

You agree to take any action necessary, as reasonably requested by Atlantis Health, to properly correct or address any deficiencies noted in the dispensing record for the Program or as a result of any regulatory inspection or audit of your records related to this Program.

By participating in this Program, you warrant that you have obtained consent from your pharmacy staff, or any other persons relating to this request, to forward their personal information to Atlantis Health, and to service providers or affiliated companies that assist us, on their behalf and that their information will be treated the same as outlined in the Privacy Statement.

By supplying your contact details, you also consent for Atlantis Health and/or Amgen to contact you for follow-up information if a safety report is identified. You agree that Atlantis Health and/or Amgen can contact you via email or telephone to seek further information regarding adverse events.

By participating in this Program, you acknowledge that you have read and understood the Australian Product Information for Repatha®, and you understand that you can seek information for this product from the Consumer Medicine Information and the Product Information.

You agree to report all adverse events, other safety findings and product quality complaints immediately to Amgen's Pharmacovigilance team, and to obtain patient consent before providing personal information when making a report.

You represent and warrant that you have not been debarred as a pharmacist pursuant to any applicable laws or regulations. Furthermore, there are no proceedings against you that could lead to your debarment. You also agree to immediately inform Atlantis Health in writing if any such proceeding is threatened or commenced.

Atlantis Health and/or Amgen reserve the right to change the Program Terms and Conditions at any time.

You have been advised by your doctor that you are suitable for EVENITY® (romosozumab) treatment and agree to participate in the Program.

You have been informed by your doctor about the EVENITY® Co-Pay Program, treatment with EVENITY®, including how to administer and its potential benefits and side effects, and any questions have been answered.

You understand that you will only be eligible to receive product at no cost† through a participating pharmacy once you meet the eligibility criteria, including proof of dispense history from your selected pharmacy.

Amgen, in its sole discretion, has the right to cease providing the EVENITY® Co-Pay Program at any time.

You are aware that in order to manage the Program, your doctor will be required to provide personal information to Atlantis Health (the Program administrator) who will collect and store your information in accordance with the privacy statement and for the purposes of administering the Program.

If you report an adverse event, with your consent, your personal information will be provided to Amgen and Amgen may need to contact you for more information. If consent is not provided, the adverse event will be reported in a de-identified manner.

† Note: pharmacies may charge a dispensing fee. These fees are not included in the Program.

You have been advised by your doctor that you are suitable for Repatha® (evolocumab) treatment and agree to participate in the Program.

You have been informed by your doctor about the Repatha® Co-Pay Program, treatment with Repatha®, including how to administer and its potential benefits and side effects, and any questions have been answered.

You understand that through the Program, you will be eligible to receive one Repatha® prescription (which includes x2 SureClick® pens) at no cost† when you have purchased two Repatha® prescriptions for the duration determined by your doctor or expanded PBS listing, whichever comes first.

Amgen, in its sole discretion, has the right to cease providing the Repatha® Co-Pay Program at any time.

You are aware that in order to manage the Program, your doctor will be required to provide personal information to Atlantis Health (the Program administrator) who will collect and store your information in accordance with the privacy statement and for the purposes of administering the Program.

If you report an adverse event, with your consent, your personal information will be provided to Amgen and Amgen may need to contact you for more information. If consent is not provided, the adverse event will be reported in a de-identified manner.

† Note: pharmacies may charge a dispensing fee. These fees are included in the Program up to the value of $18.00. Amgen does not cover any additional non-drug related costs such as consultation fees.

AUS-NP-0725-80004
Date of preparation: August 2025